PDCD1 and kidney cancer: Modern immunotherapy, specifically immune checkpoint inhibitors such as anti-programmed death receptor 1 (anti-PD-1) and anti-programmed death receptor ligand 1 (anti-PD-L1) antibodies may well be an important new modality in the treatment of kidney cancer.